Status:
TERMINATED
Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
Lead Sponsor:
University of Pittsburgh
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to investigate the combination of gemtuzumab ozogamicin, mitoxantrone and etoposide as second line therapy in patients with acute myeloid leukemia.
Detailed Description
The combination of mitoxantrone and etoposide is an active regimen in refractory/relapsed AML patients. In order to improve the efficacy of mitoxantrone and etoposide as second line therapy in patient...
Eligibility Criteria
Inclusion
- Able to understand and have the ability to provide written consent
- Between 18 and 70 years of age
- Patients with CD33 positive (determined as CD33 expression in ≥ 20% of leukemic blasts) de novo AML that did not respond to first line induction therapy
- ECOG Performance Status of 0-2
- Patients must have the following laboratory values within 48 hours prior to beginning protocol treatment: Serum creatinine ≤ 1.5 mg/ml and calculated creatinine clearance ≥ 50mL/min (using the Cockcroft-Gault equation); AST ≤ 59 IU/L; ALT ≤ 72 IU/L; Total bilirubin ≤ 1.3 mg/ml; Note: Hematologic abnormalities will not be used as a criteria for entry or exclusion.
- Patients must have left ventricular ejection fraction (LVEF) ≥50%
- Females of child-bearing potential must have a negative pregnancy test during screening and all subjects must agree to use an effective method of contraception.
Exclusion
- Patients with acute promyelocytic leukemia
- Prior use of mitoxantrone or etoposide or gemtuzumab ozogamicin
- Antecedent hematologic disorder preceding initial presentation of AML or therapy related AML
- History of thromboembolic event within the past 12 months
- Hepatitis B or C or HIV positive serology
- Symptomatic central nervous system (CNS) involvement
- History of congestive heart failure
- Myocardial infarction in the past 6 months
- Uncontrolled, life-threatening infection that is not responding to antimicrobial therapy
- History of psychiatric disorder which may compromise compliance with the protocol or which does not allow for appropriate informed consent
- Patient may not be receiving any other anti neoplastic investigational agents
- INR\> 1.5 or patient is receiving systemic anticoagulation (e.g warfarin)
- Patient undergone autologous or allogeneic stem cell transplantation
- Other active malignancies except for non-melanoma skin cancer or cervical intraepithelial neoplasia
- Women who are pregnant or breastfeeding.
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT00660036
Start Date
September 1 2008
End Date
April 1 2011
Last Update
January 15 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pittsburgh Cancer Institute / Hillman Cancer Center
Pittsburgh, Pennsylvania, United States, 15232